HORAMA is developing innovative gene therapy medicinal products in the field of rare ophthalmological diseases to preserve visual autonomy of the affected patients. The objectives are to stop disease evolution and restore visual functions with an early-stage treatment for a life without a handicap.
HORAMA focuses on the development of recombinant adeno-associated viral vectors for orphan blinding diseases without a current treatment.
Terms of collaboration
☒ Research collaboration
☐ Service provision
☐ Material supply